



SCIENTIFIC PROGRAM *(as of March 7, 2023)*

* NOTE: Each talk will include 15 minutes for Q&A

All sessions will take place in the Drawing Room of the Fairmont Chateau Laurier (Main Level).

SUNDAY, MAY 14

13.30-13:45 **Welcome and Opening Remarks**

Antoinette Le Roux, MD
CLIMOA President 2022-2023
Medical Director, Canada Life
Nanaimo, British Columbia

13:45-14:45 **Increasing Role of Cardiac MRI in Diagnosis, Stratification and Surveillance of Heart Conditions**

Ian Paterson, MD, FRCPC
Professor of Medicine, University of Ottawa;
Co-director of Cardiac MRI, University of Ottawa Heart Institute
Ottawa, Ontario

Session Objectives: to be confirmed

14:50-15:50 **The Evolving Role of Radiology in Neurological Diseases Management**

Santanu Chakraborty, MBBS, MRCP, DMRD, FRCR, FRCPC
Professor, Department of Radiology, University of Ottawa
Ottawa, Ontario

Session Objectives:

- Describe the use of imaging for assessment of patients with Stroke;
- Recognize by case examples the typical imaging appearance of Multiple Sclerosis and differentiation from nonspecific white matter disease;
- Discuss advanced imaging for diagnosis of diffuse axonal injury;
- Discuss sensitivity and limitations of different imaging modalities;
- Discuss some commonly used but confusing neuroradiology terms.

15:50-16:15 **Refreshment Break**

SUNDAY, MAY 14 *(continued)*

16:15-17:15 **New Advances in Melanoma in 2023**

Carolyn Nessim, MD, MSc, FRCSC, FACS
Surgical Oncologist, The Ottawa Hospital;
Associate Professor of Surgery, University of Ottawa;
Clinician Investigator – Cancer Therapeutics Program – OHRI;
Program Director, Surgical Oncology Fellowship Program
Ottawa, Ontario

Session Objectives:

- A general review of surgery in melanoma;
- The role Immunotherapy and targeted therapy plays in the treatment of Melanoma;
- The role of intra-lesional therapy including T-VEC;
- New Prognostic Molecular tools in Melanoma.

17:15-18:30 **Welcome Reception (Laurier Room)**

MONDAY, MAY 15

07:00-08:00 **Breakfast (Drawing Room Foyer)**

08:00-09:00 **Underwriting Initiatives and the Medical Director Role**

Dave Rengachary, MD, DBIM, MBA, FALU
Senior Vice President, USMM Underwriting, Reinsurance Group of America (RGA)
Chesterfield, Missouri, USA

Jennifer Brodeur
Vice President, Underwriting, Reinsurance Group of America (RGA)
Montreal, Quebec

Brigitte Loos, FALU, FLMI, ACS, ARA
VP and Chief Underwriter, Canada Life
Toronto, Ontario

Session Objectives:

- Discuss key underwriting trends and how the medical director role must evolve to adapt to the rapidly changing landscape
- Review emerging non-traditional roles for physician executives both within and adjacent to underwriting.
- Explore skillset gaps and developmental opportunities, formal and informal, to best equip the medical director going forward.

09:05-10:05 **Long COVID**

Tim Meagher, MD, FRCPC, FACP, FRCPI
Vice President and Medical Director, Munich Re Canada
Montreal, Quebec

Session Objectives:

- Provide a critical analysis of long COVID, emphasising the similarities and differences with other post-viral syndromes;
- Discuss rehabilitation initiatives, disease time-course and prospects for full recovery;
- Develop a better understanding of the long COVID spectrum, an appreciation of the divergent data around disability and sense of the expected evolution of long COVID over the next years.

10:05-10:20 **Refreshment Break**

10:20-11:20 **Innovations in Risk Stratification and Therapeutics for Localized and Advanced Prostate Cancer**

Scott Morgan, MD, MSc, FRCPC
Radiation Oncologist, The Ottawa Hospital Cancer Centre;
Associate Professor, Division of Radiation Oncology, University of Ottawa
Ottawa, Ontario

MONDAY, MAY 15 *(continued)*

Session Objectives:

- Review established clinical and pathologic risk factors for prostate cancer recurrence and mortality;
- Examine emerging biomarkers in localized prostate cancer and their potential applications;
- Highlight innovations in local therapy for localized and advanced prostate cancer;
- Review advances in systemic therapies for localized and metastatic prostate cancer.

11:25-12:25 **DI Claims: The Clinical and Insurance Perspective**

Kim Minish, MD, CCFP, FCFP
Assistant Medical Director, Canada Life
Winnipeg, Manitoba

Parminder Ghura, MBBS, MRO, CCFP, MBA, LL.M, MFOM, MSc(OccMed)
Medical Consultant;
Occupational Physician;
Medical Review Officer, DriverCheck;
Addiction Medicine Physician, Canadian Addiction Treatment Centres
Ottawa, Ontario

Session Objectives:

- List three common disability underwriting assumptions that can lead to inaccurate assessment and management of disability risk;
- Describe common knowledge gaps about disability insurance in the clinicians who care for disability claimants;
- Identify common behaviours and beliefs of treating clinicians which may affect the occurrence of a disability claim, or its outcome.

12:30-13:30 **Lunch (Canadian Room)**

MONDAY, MAY 15 *(continued)*

13:30-14:30 **Canada Four Years after Cannabis Legalization**

Jonathan Bertram, MD, CCFP
Staff Physician, Concurrent Outpatient Medical & Psychosocial Addiction Support Services;
Addictions & Pain Physician, Clarington Family Health Organization;
Vice Chair, Addictions Medicine Section, Ontario Medical Association;
Hub Member FNIM (First Nations Inuit Metis) ECHO-CAMH;
Consultant Physician to Shkaabe Makwa – CAMH;
Consulting Physician, Canadian Mental Health Association - Waterloo Wellington;
Consulting Physician, Community Outreach Programs in Addiction – Reconnect Mental Health Services
Belleville, Ontario

Session Objectives:

- Describe the demographics and usage patterns of Canadians since legalization of Cannabis;
- Define cannabis use disorder and its intersection with medical cannabis use;
- Discuss specific concerns/ideas about cannabis use in older populations.

14:35-15:35 **Wearables**

Yaariv Khaykin, MD
Electrophysiologist, Pace Cardiology
Toronto, Ontario

Session Objectives: to be confirmed

15:35-15:50 **Refreshment Break**

15:55-16:55 **Long-Term Complications of Prematurity**

Anne Monique Nuyt, MD
Chief, Department of Pediatrics, Centre hospitalier universitaire Sainte-Justine;
Professor, Department of Pediatrics, Université de Montréal
Montreal, Quebec

Thuy Mai Luu, MDCM, MSc, FRCP(C)
Staff pediatrician, Division of general pediatrics;
Clinical Associate Professor, Faculty of medicine, Université de Montreal;
Clinical scientist, CHU Sainte-Justine Research Centre;
Director, Canadian Neonatal Follow-Up Network.
Montreal, Quebec

Session Objectives:

- Provide an overview of the multiple health impacts of premature birth, with a particular focus on the development of cardiovascular disease in adulthood;
- Develop a better understanding of how premature birth may affect health in adult life, and a consideration during life insurance risk analysis.

TUESDAY, MAY 16

07:00-08:00 **Breakfast (Drawing Room Foyer)**

08:00-09:15 **No Guidance? Ways to Use Clinical Data to Assess the Mortality Risk**

François Sestier, MD, PhD, FRCPC, FACC, DBIM, CIME
Medical Director, Blue Cross Canassurance Group;
Professor of Medicine, Université de Montréal
Montreal, Quebec

Brad Heltemes, MD, DBIM, FAAIM
VP & Medical Director, R&D/Innovation, Munich Re
Minneapolis, MN, USA

Session Objectives: to be confirmed

09:20-10:10 **MI Redefined and Refined**

François Grondin, MD
Medical Director, Desjardins Sécurité financière
Lévis, Quebec

Session Objectives:

At the end of the session, the participant will:

- Have a better understanding of the diagnostic criteria of myocardial infarction and its subtypes;
- Have an enhanced knowledge of the non atherosclerotic forms of myocardial infarction;
- Better assess mortality risk of the various forms of myocardial infarction.

10:10-10:30 **Refreshment Break**

10:30-11:30 **EKG Workshop**

Ross MacKenzie, MD, FRCPC, FACC, FAAIM
Editor, *Journal of Insurance Medicine*
Toronto, Ontario

Session Objectives:

- Review ECG abnormalities that should not be missed due to their association with high mortality;
- Discuss the morphological aspects of commonly encountered ECG challenges that might impact applicant mortality.

TUESDAY, MAY 16 *(continued)*

11:35-12:35 **COVID and Non-COVID-19 Excess Mortality and Emerging Trends – Accessing Healthcare in Canada – An Overview of Our HCS**

Jeff Latimer
Statistics Canada
Ottawa, Ontario

John Lefebvre, MD, FRCPC
VP & Senior Medical Director, Reinsurance Group of America (RGA)
Toronto, Ontario

Session Objectives:

- Better understand the mortality excess directly and indirectly associated with COVID 19;
- Mortality trends predicted for Canada indirectly and directly due to COVID;
- Review the impact of COVID on the healthcare system present and future.

12:40-13:40 **Lunch and CLIMOA Annual General Meeting (Canadian Room)**

13:40-14:40 **Evolving Treatment of Valvular Heart Disease**

Roy Masters, MD, FACS, FRCSC
Professor of Surgery, University of Ottawa Heart Institute
Ottawa, Ontario

Session Objectives:

- Review the Epidemiology of Valvular Heart Disease;
- Review the evolution of the treatment of Valvular Heart Disease;
- Review the current and evolving treatments of Valvular Heart Disease and their Outcomes.

14.40-15.40 **Precision Medicine – Current State and Future Directions**

Christopher Trevors, MS, CGC
National Director, Genetic Health Solutions, Dynacare
Toronto, Ontario

Session Objectives:

- Describe what precision medicine is and clinical areas of application;
- List the clinical applications, guidelines and barriers to adoption of Pharmacogenomics;
- Identify the current clinical use and future potential of Precision oncology.

15:40-15:45 **Closing Remarks**

Antoinette Le Roux, MD
CLIMOA President 2022-2023
Medical Director, Canada Life
Nanaimo, British Columbia